The earnings call presented a mixed picture, with stable year-to-date revenues, strategic expansions, successful patent approval, and financial agreements being positive aspects. However, these were countered by a decline in third-quarter revenues, increased legal costs, and a higher net loss.

Company Guidance

During Biofrontera Inc.'s third-quarter 2025 financial results and business update conference call, CEO Hermann Luebbert provided guidance indicating a transient revenue dip due to a lack of buy-in opportunities following the previous year's price increase. The company anticipates strong revenue growth in the fourth quarter of 2025, driven by an expanded installed base of approximately 750 RhodoLED lamps and potential new indications for Ameluz. Financially, Biofrontera reported a 22% year-over-year decline in third-quarter revenues to $7.0 million, attributed to the 2024 price increase effect, while operating expenses decreased to $13.3 million. The net loss for the quarter was $6.6 million, with an adjusted EBITDA of negative $6.0 million. For the first nine months of 2025, total revenues were relatively flat at $24.6 million, with operating expenses at $40.5 million. The company recently completed a strategic agreement with Biofrontera AG, acquiring all U.S. rights for Ameluz and RhodoLED, expected to enhance gross margins and profitability. Additionally, the company has secured an $11 million investment and completed the Xepi license divestiture, positioning for cash flow breakeven in fiscal year 2026.

Stable Year-to-Date Revenues

Biofrontera's year-to-date revenues until September 30, 2025, remained approximately flat compared to the same period in 2024, despite fewer buying opportunities and no price increase.

Strategic Expansion and Patent Approval

Biofrontera plans to submit a new FDA application for Ameluz to treat superficial basal cell carcinoma, and they received patent approval for a new formulation of Ameluz, extending protection through December 2043.

Transformational Agreement and Investment

Biofrontera completed a significant agreement with Biofrontera AG, acquiring all U.S. rights for Ameluz and RhodoLED, expected to enhance gross margins. They also secured an $11 million investment from institutional investors.

Xepi Divestment and Financial Position

Completed the sale of Xepi license, receiving $3 million at closing, with potential for an additional $7 million. This, along with other financing, is expected to support cash flow breakeven by fiscal year 2026.

Biofrontera (BFRI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BFRI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 03, 2026	2025 (Q4)	0.15 / -	-0.47	―	―	―
Nov 13, 2025	2025 (Q3)	-0.58 / -0.62	-0.98	36.73% (+0.36)	―
Aug 13, 2025	2025 (Q2)	-0.42 / -0.57	-0.05	-1040.00% (-0.52)	―
May 15, 2025	2025 (Q1)	-0.21 / -0.47	-2.88	83.68% (+2.41)	―
Mar 21, 2025	2024 (Q4)	-0.03 / -0.19	4.45	-104.27% (-4.64)	―
Nov 13, 2024	2024 (Q3)	-0.83 / -0.98	-4.64	78.88% (+3.66)	―
Aug 14, 2024	2024 (Q2)	-0.77 / -0.05	-7.23	99.31% (+7.18)	―
May 15, 2024	2024 (Q1)	-1.17 / -2.88	-5.6	48.57% (+2.72)	―
Mar 15, 2024	2023 (Q4)	-1.19 / 4.45	-2.1	311.90% (+6.55)	―
Nov 09, 2023	2023 (Q3)	-3.79 / -4.64	-2.2	-110.91% (-2.44)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BFRI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.95	$0.97	+2.11%
May 15, 2025	$0.70	$0.65	-7.14%
Mar 21, 2025	$1.03	$0.86	-16.50%
Nov 13, 2024	$0.83	$0.70	-15.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Biofrontera (BFRI) report earnings?

Biofrontera (BFRI) is schdueled to report earning on Apr 03, 2026, Before Open (Confirmed).

What is Biofrontera (BFRI) earnings time?

Biofrontera (BFRI) earnings time is at Apr 03, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BFRI EPS forecast?

BFRI EPS forecast for the fiscal quarter 2025 (Q4) is 0.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing